Welcome to Consilient Health

My Consilient       Generics       How to Order?       What are generics? Generic medicines contain the same active ingredients as the original, brand name drugs and are therefore interchangeable with the originator product. Generics are used for the same symptoms as the original drug and are bioequivalent. They provide the same quality, safety and efficacy as the original brand name product and undergo strict audits before being licensed and given market approval by EU or national medicines authorities. Pharmaceutical companies spend vast amounts of money on researching and developing new drugs. New drugs enjoy patent protection for at least 20 years, which gives the manufacturer the exclusive right to market and sell their drug, and to receive a very high return on their original investment in R&D. Once the patents on new drugs expire, competing drug companies can apply to manufacture the same drug as its generic equivalent. After a generic drug obtains approval, increased competition keeps the price down. Why pay more for the same product? The availability of bio-equivalent generic drug provides consumers with increased choice along with the opportunity to save money. Cost savings will vary but can be significant for those with serious and chronic illnesses. Patients are increasingly asking for the generic version of popular branded drugs at their local pharmacy. Generic drugs are instrumental in providing low cost choice without sacrificing quality, safety or efficacy. Government funded national healthcare plans stand to reap huge benefits from large-scale use of generic medicines when caring for their elderly and chronically ill citizens. Using generic drugs entails substantial savings for governments, so they can maintain a high level of care despite an increasingly aging population. The generic drug market in Europe is in a position to experience substantial market growth. Generics in some member states can account for up to 50% of all prescriptions and this is forecast to reach 60% by 2007. Pressures to contain costs on healthcare services and organisations will lead to amplified implementation of generic replacement and prescribing practices in many EU Member States. Patent expiry of leading drugs and EU enlargement are inherent in the growth and expansion of the EU generics sector to 2007. Consilient Health launches Losartan 2nd March 2010 Consilient Health is proud to announce the launch of its Losartan potassium 12.5/25/50/100mg film-coated tablets and Losartan potassium/ Hydrochlorothiazide 50/12.5mg and 100/25mg film-coated tablets in blister packs of 28's. Consilient Health launches Levocetirizine 28th September 2009 Consilient Health 1st to Market Again! Clopidogrel 75mg f/c Tablets 1st July 2009 more... Consilient Health launches Pantoprazole 6th May 2009 Consilient Health elected member of British Generic Manufacturers Association (BGMA) 21st January 2009 Consilient Health launches Alventa XL (Venlafaxine) 8th December 2008 Consilient Health launches Rawel XL (Indapamide) 22nd September 2008 Consilient Health launches Bicalutamide 8th July 2008 Consilient Health launches Mirtazapine Orodispersible Tablets 13th June 2008 Consilient Health launches Perindopril 29th May 2008 Nazdol MR Tablets - UK 1st to market success for Consilient Health! 5th March 2008 more... Consilient Health launches Risperidone 10th December 2007 Consilient Health launches Amlodipine 2nd October 2007 Consilient Health launches Alendronic Acid 5th September 2007 Consilient Health launches Carvedilol 5th September 2007 Consilient Health launches Mirtazapine 24th July 2007 Consilient Health launches Finasteride 29th May 2007 Consilient Health launches Glimepiride 16th October 2006 Consilient Health launches Sumatriptan 22nd May 2006 Consilient Health launches Sertraline 9th May 2006 Consilient Health launches Tamsulosin 13th April 2006 Consilient Health launches Omeprazole 6th March 2006 Consilient Health launches Lansoprazole 12th December 2005 more... Consilient Health elected member of European Generics Association (EGA) 21st November 2005 Consilient Health receives Wholesale Dealers License 19th September 2005 Consilient Health launches Terbinafine 2nd September 2005 Consilient Health launches Lamotrigine 26th July 2005 Consilient Health enters UK and Dutch Market 26th July 2005 more... First product release in Denmark 9th May 2005